Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
[43] Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cell: Novel targets for anti-<br />
angiogenesis therapy. Nat Rev Cancer 2: 826-835, 2002<br />
[44] Zebrowski BK, Yano S, Liu W, et al: Vascular endotelial growth factor levels and induction of<br />
permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368, 1999<br />
[45] Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in<br />
malignant ascites. Ann Surg Oncol 6: 373-378, 1999<br />
[46] Masashi Narazaki, Giovanna Tosato Targeting Coaugulation to the Tumor Microvasculature:<br />
Perspectives and Therapeutic Implications From Preclinical Stu<strong>di</strong>es Journal of the National Cancer Institute,<br />
Vol. 97No.10, May 18, 2005<br />
[47] Ferrara N, Davis- Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25<br />
[48] Folkman J, Klagsbr<strong>un</strong> M 1987 Angiogenic factors. Science 235: 442-447<br />
[49] Folkman J,1991 What is the evidence that tumors are angiogenesi-dependent?J Natl Cancer Inst 82:4-6<br />
[50] Gasparini G. breast cancer : molecular genetics, pathogenesis and therapeutics. In : Bow-cock A e<strong>di</strong>tor.<br />
Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis: Totowa (NJ): Humana<br />
Press, Inc.; p.347-71.<br />
[51] Sledge GW Jr.Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.<br />
Semin Oncol 2002; 29 (3 suppl11): 104-10<br />
[52] Konecny GE; Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth<br />
factor expression pre<strong>di</strong>cts clinical outcome in primary breast cancer parients. Clin Cancer Res 2004; 10(5):<br />
1706-16.<br />
[53] Weidner N, Semple JP, Welch W, Folkman J 1991 Tumor angiogenesis and metastasis. Correlation in<br />
invasive breast carcinoma. N Engl J Med 324: 1-8<br />
[54] Horak ER, Leek R, Klenk N, Leje<strong>un</strong>e S, Smith K, Stuart M, Greenall M, Harris AL 1992 Quantitative<br />
angiogenesis asessed by anti-PECAM antibo<strong>di</strong>es. Correlation with node metastasis and survival in breast<br />
cancer. Lancet 340: 1120-1124<br />
Maria Pittalis<br />
<strong>Valutazione</strong> <strong>di</strong> <strong>efficacia</strong> <strong>di</strong> <strong>un</strong> <strong>antiangiogenetico</strong> (<strong>Bevacizumab</strong>) associata a chemioterapia in pazienti con carcinoma<br />
della mammella metastatico<br />
Tesi <strong>di</strong> dottorato in scienze Biome<strong>di</strong>che-Epidemiologia molecolare dei tumori<br />
Università degli Stu<strong>di</strong> <strong>di</strong> Sassari<br />
84
Change language